Aktuellt
SENASTE
The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development milestone for the company. Delivered by development partner G&H I ITL, the prototypes will now undergo rigorous stress-testing and be utilised in the pivotal pre-validation study set to refine the high-sensitivity troponin test and platform. This progress solidifies the timeline towards the 2025 clinical performance study, setting Prolight up for IVDR certification and a groundbreaking commercial launch of high sensitive troponin in 2026. With proof-of-performance for high sensitivity troponin, a first commercial prototype, which raises the likelihood to get to launch to 82% (75%), and the potential to expand to BNP and D-Dimer, we now find support for a fair value of SEK 0.9-1.0 (0.85-0.92) per share.
LÄS MER
